Verano Holdings (VRNO) Common Equity (2021 - 2026)
Verano Holdings' (VRNO) quarterly Common Equity came in at $688.3 million in Q1 2026, down 26.9% year-on-year from $941.6 million in Q1 2025, and down 2.25% on a QoQ basis from $704.2 million in Q4 2025.
Verano Holdings (VRNO) Common Equity (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 6 years of Common Equity data on file, last reported at $688.3 million in Q1 2026.
- On a quarterly basis, Common Equity fell 26.9% year-over-year to $688.3 million in Q1 2026; TTM through Mar 2026 was $688.3 million, a 26.9% decrease from a year earlier, with the FY2025 full-year figure at $704.2 million, down 25.94% from the prior year.
- Common Equity for Q1 2026 stood at $688.3 million, down from $704.2 million in the prior quarter.
- Over the last five years, Common Equity for VRNO reached as high as $1.5 billion in Q2 2022 and fell as low as $688.3 million in Q1 2026.
- Historically, Common Equity has averaged $1.2 billion across 5 years, with a median of $1.2 billion in 2024.
- Across the five-year window, Common Equity soared 6973.1% in 2022 and fell 27.27% in 2025, its largest moves.
- Year by year, Common Equity stood at $1.3 billion in 2022, then retreated by 7.56% to $1.2 billion in 2023, then decreased by 23.33% to $950.8 million in 2024, then retreated by 25.94% to $704.2 million in 2025, then retreated by 2.25% to $688.3 million in 2026.
- Per Business Quant data, the three most recent Common Equity figures were $688.3 million in Q1 2026, $704.2 million in Q4 2025, and $885.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 21.93 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.23 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 3.23 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 47.38 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 5.90 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 56.13 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 3.41 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.50 Bn |
| 10 | Verano Holdings | 2.02 Bn | 1.94 Bn | 98.98 Mn | 688.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 688.35 Mn |
| Dec 31, 2025 | 704.16 Mn |
| Sep 30, 2025 | 885.86 Mn |
| Jun 30, 2025 | 927.23 Mn |
| Mar 31, 2025 | 941.60 Mn |
| Dec 31, 2024 | 950.82 Mn |
| Sep 30, 2024 | 1.22 Bn |
| Jun 30, 2024 | 1.22 Bn |
| Mar 31, 2024 | 1.24 Bn |
| Dec 31, 2023 | 1.24 Bn |
| Sep 30, 2023 | 1.31 Bn |
| Jun 30, 2023 | 1.33 Bn |
| Mar 31, 2023 | 1.34 Bn |
| Dec 31, 2022 | 1.34 Bn |
| Sep 30, 2022 | 1.54 Bn |
| Jun 30, 2022 | 1.55 Bn |
| Dec 31, 2021 | 1.48 Bn |
| Sep 30, 2021 | 42.40 Mn |
| Jun 30, 2021 | 21.90 Mn |